Technical Analysis for SBFM - Sunshine Biopharma Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 4.49% | |
| Wide Bands | Range Expansion | 4.49% | |
| Narrow Range Bar | Range Contraction | 4.21% | |
| Inside Day | Range Contraction | 4.21% | |
| Wide Bands | Range Expansion | 4.21% | |
| Shooting Star Candlestick | Bearish | 3.39% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | 1 day ago |
| Up 10% | 1 day ago |
| 10 DMA Resistance | 2 days ago |
| 20 DMA Resistance | 2 days ago |
| Up 5% | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
Sunshine Biopharma Inc. Description
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also provides generic prescription drugs for the treatment of breast cancer, prostate cancer, and benign prostatic hyperplasia; and Essential 9, a dietary supplement tablet. Sunshine Biopharma, Inc. has a license agreement with the University of Georgia to advance the development of two anti-coronavirus compounds in parallel with its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. was founded in 2006 and is headquartered in Pointe-Claire, Canada.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Cancer Pharmaceutical Breast Cancer Lymphoma Prostate Cancer Dietary Supplement Treatment Of Breast Cancer Pancreatic Cancer Small Cell Lung Cancer Leukemia Benign Prostatic Hyperplasia Hyperplasia Histopathology Prostate
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 67.01 |
| 52 Week Low | 0.75 |
| Average Volume | 3,371,333 |
| 200-Day Moving Average | 22.80 |
| 50-Day Moving Average | 4.40 |
| 20-Day Moving Average | 0.94 |
| 10-Day Moving Average | 0.93 |
| Average True Range | 0.56 |
| RSI (14) | 13.04 |
| ADX | 54.31 |
| +DI | 18.02 |
| -DI | 35.92 |
| Chandelier Exit (Long, 3 ATRs) | 1.99 |
| Chandelier Exit (Short, 3 ATRs) | 2.44 |
| Upper Bollinger Bands | 1.23 |
| Lower Bollinger Band | 0.66 |
| Percent B (%b) | 0.47 |
| BandWidth | 60.14 |
| MACD Line | -1.15 |
| MACD Signal Line | -1.41 |
| MACD Histogram | 0.2577 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.11 | ||||
| Resistance 3 (R3) | 1.11 | 1.06 | 1.08 | ||
| Resistance 2 (R2) | 1.06 | 1.01 | 1.05 | 1.07 | |
| Resistance 1 (R1) | 0.99 | 0.98 | 1.02 | 0.99 | 1.06 |
| Pivot Point | 0.94 | 0.94 | 0.95 | 0.94 | 0.94 |
| Support 1 (S1) | 0.87 | 0.89 | 0.91 | 0.87 | 0.80 |
| Support 2 (S2) | 0.82 | 0.86 | 0.82 | 0.79 | |
| Support 3 (S3) | 0.75 | 0.82 | 0.78 | ||
| Support 4 (S4) | 0.75 |
